CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma

Published:April 08, 2022DOI:


      Background aims

      Chimeric antigen receptor (CAR) T-cell therapy can be associated with significant toxicities. CAR-engineered natural killer (NK) cells provide a safer alternative while maintaining anti-tumor effects. Activated NK (aNK) cells are a clinical-grade cellular product obtained from the NK-92 cell line that have demonstrated both safety and potent cytotoxicity toward a wide range of cancers in phase 1 trials. Genetically engineered variants of aNK cells expressing a high-affinity Fc receptor (haNK) or co-expressing a CAR (t-haNK) are currently in phase 1/2 clinical trials. A key factor in the efficacy of cellular immunotherapies is biodistribution and tumor infiltration, which affect the local effector:target ratio. The chemokines CCL19 and CCL21 can drive recruitment of CCR7 receptor-expressing immune cells to secondary lymphoid organs.


      Since NK-92 cells do not spontaneously express CCR7, clinical-grade aNK cells were transfected with a non-viral vector containing the CCR7 receptor, an anti-CD19 CAR and a high-affinity CD16 Fc receptor.


      CCR7-engineered CD19 t-haNK showed significant migration in vitro toward K562 cells engineered to secrete CCL19. This observation was confirmed in a NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mouse model in which subcutaneous tumors of CCL19-expressing K562 cells displayed a higher number of infiltrating CCR7_CD19 t-haNK cells than CCR7-negative CD19 t-haNK cells. In NSG mice inoculated either intravenously or subcutaneously with CCL19-secreting Raji cells, treatment with CCR7_CD19 t-haNK improved survival and tumor control compared with CD19 t-haNK or vehicle.


      Expression of CCR7 receptor by off-the-shelf t-haNK cells improves their homing toward lymph node chemokines both in vitro and in vivo, resulting in superior tumor control.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • June C.H.
        • Sadelain M.
        Chimeric Antigen Receptor Therapy.
        N Engl J Med. 2018; 379: 64-73
        • Hughes C.E.
        • Nibbs R.J.B.
        A guide to chemokines and their receptors.
        FEBS J. 2018; 285: 2944-2971
        • Tanaka T.
        • Bai Z.
        • Srinoulprasert Y.
        • et al.
        Chemokines in tumor progression and metastasis.
        Cancer Sci. 2005; 96: 317-322
        • Muller A.
        • Homey B.
        • Soto H.
        • et al.
        Involvement of chemokine receptors in breast cancer metastasis.
        Nature. 2001; 410: 50-56
        • Comerford I.
        • Harata-Lee Y.
        • Bunting M.D.
        A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system.
        Cytokine Growth Factor Rev. 2013; 24: 269-283
        • Rizeq B.
        • Malki M.I.
        The role of CCL21/CCR7 chemokine axis in breast cancer progression.
        Cancers. 2020; 12: 1036
        • Mourcin F.
        • Verdiere L.
        • Roulois D.
        • et al.
        Follicular lymphoma triggers phenotypic and functional remodeling of the human lymphoid stromal cell landscape.
        Immunity. 2021; 54: 1788
        • Franks S.E.
        • Wolfson B.
        • Hodge J.W.
        Natural Born Killers: NK Cells in cancer therapy.
        Cancers. 2020; 12: 2131
        • Yang L.
        • Huang C.
        • Wang C.
        • et al.
        Overexpressed CXCR4 and CCR7 on the surface of NK92 cell have improved migration and anti-tumor activity in human colon tumor model.
        Anticancer Drugs. 2020; 31: 333-344
        • Pesce S.
        • Moretta L.
        • Moretta A.
        • et al.
        Human NK cell subsets redistribution in pathological conditions: a role for CCR7 receptor.
        Front Immunol. 2016; 7: 414
        • Carlsten M.
        • Levy E.
        • Karambelkar A.
        • et al.
        Efficient mRNA-based genetic engineering of human NK cells with high-affinity CD16 and CCR7 augments rituximab-induced ADCC against lymphoma and targets NK cell migration toward the lymph node-associated chemokine CCL19.
        Front Immunol. 2016; 7: 105
        • Gong J.H.
        • Maki G.
        • Klingemann H.G.
        Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.
        Leukemia. 1994; 8: 652-658
        • Klingemann H.
        Are natural killer cells superior CAR drivers?.
        Oncoimmunology. 2014; 3: e28147
        • Tam Y.K.
        • Maki G.
        • Miyagawa B.
        • et al.
        Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy.
        Hum Gene Ther. 1999; 10: 1359-1373
        • Arai S.
        • Meagher R.
        • Swearingen M.
        • et al.
        Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial.
        Cytotherapy. 2008; 10: 625-632
        • Boyiadzis M.
        • Agha M.
        • Redner R.L.
        • et al.
        Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and re-lapsed acute myeloid leukemia.
        Cytotherapy. 2017; 19: 1225-1232
        • Tonn T.
        • Schwabe D.
        • Klingemann H.G.
        • et al.
        Treatment of patients with advanced cancer with the natural killer cell line NK-92.
        Cytotherapy. 2013; 15: 1563-1570
        • Williams B.A.
        • Law A.D.
        • Routy B.
        • et al.
        A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell trans-plantation shows safety and evidence of efficacy.
        Oncotarget. 2017; 8: 89256-89268
        • Boissel L.
        • Campbell K.
        • Nichols K.
        • et al.
        Abstract 2302: an ‘off the shelf,’ GMP-grade, IL-2-independent NK cell line expressing the high-affinity Fc-receptor to augment antibody therapeutics.
        Cancer Res. 2016; 76 (Abstract nr 2302): 2302
        • Jochems C.
        • Hodge J.W.
        • Fantini M
        • et al.
        An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele.
        Oncotarget. 2016; 7: 86359-86373
        • Friedman J.
        • Padget M.
        • Lee J.
        • et al.
        Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
        Oral Oncol. 2019; 90: 38-44
        • Jochems C.
        • Hodge J.W.
        • Fantini M.
        • et al.
        ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.
        Int J Cancer. 2017; 141: 583-593
        • Konstantinidis K.V.
        • Alici E.
        • Aints A.
        • et al.
        Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells.
        Exp Hematol. 2005; 33: 159-164
        • Robbins Y.
        • Greene S.
        • Friedman J.
        • et al.
        Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
        Elife. 2020; 9: e54854
        • Burger M.C.
        • Zhang C.
        • Harter P.N.
        • et al.
        CAR-Engineered NK Cells for the treatment of glioblastoma: Turning innate effectors into precision tools for cancer immunotherapy.
        Front Immunol. 2019; 10: 2683
        • Boissel L.
        • Betancur M.
        • Wels W.S.
        • et al.
        Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.
        Leuk Res. 2009; 33: 1255-1259
        • Nicholson I.C.
        • Lenton K.A.
        • Little D.J.
        • et al.
        Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma.
        Mol Immunol. 1997; 34: 1157-1165
        • Al-Mansour M.
        • Al-Foheidi M.
        • Ibrahim E.
        Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis.
        Mol Clin Oncol. 2020; 13: 33
        • Di Stasi A.
        • De Angelis B.
        • Rooney C.M.
        • et al.
        T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model.
        Blood. 2009; 113: 6392-6402
        • Berahovich R.D.
        • Lai N.L.
        • Wei Z.
        • et al.
        Evidence for NK cell subsets based on chemokine receptor expression.
        J Immunol. 2006; 177: 7833-7840
        • Hong H.S.
        • Ahmad F.
        • Eberhard J.M.
        • et al.
        Loss of CCR7 expression on CD56(bright) NK cells is associated with a CD56(dim)CD16(+) NK cell-like phenotype and correlates with HIV viral load.
        PLoS One. 2012; 7: e44820
        • Yan Y.
        • Chen R.
        • Wang X.
        • et al.
        CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and pPrevention.
        Front Cell Dev Biol. 2019; 7: 212
        • Levy E.R.
        • Clara J.A.
        • Reger R.N.
        • et al.
        RNA-seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking.
        Cancers. 2021; 13: 872